FDA Approves YARTEMLEA as First-Ever Treatment for TA-TMA
Omeros secures landmark approval for a life-saving therapy in adults and children following stem cell transplant The U.S. Food and ...
Tag: Movers
Highway Holdings Moves to Expand Automotive Capabilities With German Acquisition
Proposed majority stake in Regent-Feinbau aims to strengthen OEM exposure and unlock growth in China and Europe Highway Holdings Limited ...
ServiceNow Makes $7.75 Billion Bet on Cybersecurity With Armis Acquisition
Largest-ever deal aims to strengthen AI-era defenses, even as investors question deal pace ServiceNow (SNOW) announced Tuesday that it has ...
CoreWeave Positioned for a Strong Rally—Could Break $100 by Early 2026
Bullish sentiment builds as AI infrastructure demand and long-term contracts underpin growth CoreWeave (CRWV), a specialist in AI-optimized cloud infrastructure, ...
Nike Shows Early Signs of Recovery as Wholesale Strength Offsets Direct Weakness
Tariffs and digital softness weigh on margins, but leadership signals confidence in long-term turnaround Nike (NKE) reported mixed results for ...
Rivian Bets on Vertical Integration to Power Its Autonomous Future
CEO RJ Scaringe outlines the EV maker’s AI-driven roadmap toward personal Level 4 autonomy At Rivian’s (RIVN) Autonomy and AI ...
Hut 8 Secures $7 Billion Data Center Lease Backed by Google at River Bend Campus
Landmark 15-year agreement positions Hut 8 at the center of next-generation AI infrastructure buildout Hut 8 Corp. (HUT) has taken ...
Micron Posts Record Revenue and Profit in Fiscal Q1 2026
AI-driven demand fuels margin expansion and strong cash generation Micron Technology (MU) delivered a standout start to fiscal 2026, reporting ...
Bitcoin Treads Water Near $86,000 as Macro Fears Cloud Year-End Outlook
Fed leadership uncertainty, tax-driven selling, and “whale” activity weigh on crypto sentiment Bitcoin (BTC) hovered near $86,000 on Wednesday, struggling ...
Processa Pharmaceuticals Reports Promising Phase 2 Results for Breast Cancer Therapy
NGC-Cap shows enhanced cancer-killing exposure with comparable safety ahead of 2026 interim analysis Processa Pharmaceuticals (PCSA) provided a positive clinical ...
